




February 16, 2022
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO

Announcement U.S. Subsidiary (AnGes USA, Inc.) Office Relocation and the Appointment of Mr. Masami Yuhara as the CEO of AnGes USA, Inc.

AnGes, Inc. (Osaka, Japan; President and CEO, Ei Yamada) (“AnGes”) announced that it has relocated its U.S. subsidiary, AnGes USA, Inc. (“AnGes USA”) from Bethesda, Maryland to Jersey City, New Jersey on February 1, 2022. It further announced that Mr. Masami Yuhara was appointed CEO of AnGes USA.

The northeast region of the U.S. (from Massachusetts to Pennsylvania) is known as one of the biggest pharma clusters where global pharmaceutical and start-up venture companies are located. A diverse network of talented scientists and support personnel experienced in drug discovery research as well as clinical development are also located in this Region of the US. Therefore, it is the ideal environment to promote the clinical development of Novel Therapeutic Agents in the U.S., as well as to find business opportunities for various types of partnership (out-licensing of AnGes pipeline products, in-licensing of innovative products/technologies to AnGes and other alliances).

Upon this important turning point, AnGes persistently drives our commitment to providing ‘the next-generation biopharmaceuticals (genetic medicines and therapeutic vaccines) for patients as promptly as possible by accelerating the clinical development and expanding the business in the U.S.



Address:
111 Town Square Place, Suite 1507, Jersey City, New Jersey, 07310 USA

AnGes, Inc.
Public Relations & Investor Relations Group
<https://www.anges.co.jp/en/>